Champions Oncology, Inc. (CSBR) EPS Estimated At $0.04

November 8, 2018 - By Jeanette Kaplan

Champions Oncology, Inc. (NASDAQ:CSBR) Logo

Analysts expect Champions Oncology, Inc. (NASDAQ:CSBR) to report $0.04 EPS on December, 6.They anticipate $0.05 EPS change or 500.00 % from last quarter’s $-0.01 EPS. CSBR’s profit would be $446,575 giving it 87.38 P/E if the $0.04 EPS is correct. After having $0.04 EPS previously, Champions Oncology, Inc.’s analysts see 0.00 % EPS growth. The stock decreased 7.48% or $1.13 during the last trading session, reaching $13.98. About 83,117 shares traded. Champions Oncology, Inc. (NASDAQ:CSBR) has risen 168.61% since November 9, 2017 and is uptrending. It has outperformed by 152.99% the S&P500.

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. The company has market cap of $156.08 million. The Company’s Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It currently has negative earnings. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services.

More important recent Champions Oncology, Inc. (NASDAQ:CSBR) news were published by: which released: “48 Biggest Movers From Yesterday” on October 30, 2018, also published article titled: “UAA, WFT, AKAM and SN among midday movers (10/30/2018)”, published: “64 Biggest Movers From Yesterday” on October 31, 2018. More interesting news about Champions Oncology, Inc. (NASDAQ:CSBR) was released by: and their article: “55 Stocks Moving In Tuesday’s Mid-Day Session” with publication date: October 30, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.